Cheap Impact?

A new online tool allows researchers to compare open-access journal publication fees with article influence, and reveals that you don’t necessarily get what you pay for.

Written byDan Cossins
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, VMENKOVThe open-access journals that charge the most to publish in their pages don’t always have the biggest impact, according to a new, free-to-access interactive online tool. The service, which allows researchers to compare the publication price and influence of hundreds of open-access journals, reveals that publication fees don’t correlate very strongly with influence.

Launched last month to help create more transparency in the open-access journal market, Cost Effectiveness for Open Access Journals incorporates data on publication price and article influence, based on various citation measures, for 657 open-access journals indexed by Thomson Reuters. The tool was developed as part of the Eigenfactor Project, which seeks alternative ways to rank and map science.

“We have brought together a way of measuring prestige and price and come up with a metric that can be used by authors to help them decide between the different venues they could publish in,” Jevin West of the University of Washington in Seattle, who led the development of the tool, told Nature. “We hope to clean up a little of the predatory publishing, where publishers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies